
A blood test measuring an RNA signal called Tu-Stroma detected microscopic STIC lesions in study samples, potentially moving ovarian-cancer detection earlier than visible tumours. That is a meaningful research advance because these lesions may precede high-grade serous ovarian cancer, the most common and deadliest form of ovarian cancer. It is not, however, a screening test ready for clinical use.
Researchers from the Hoag Family Cancer Institute and collaborating centres developed the test and analysed samples from 506 people. The group included women with STIC lesions, diagnosed serous ovarian cancer, benign adnexal changes, and no ovarian or fallopian-tube abnormalities. Nauka w Polsce reported that Tu-Stroma levels were elevated in women with STIC lesions and in patients with established cancer, including very early-stage disease.
In an additional validation group, the test detected STIC lesions in 92.3% of women who had them and correctly returned a negative result for 98.2% of healthy women. The report also says the test distinguished pre-invasive lesions from healthy tissue more effectively than CA125, a marker used in ovarian-cancer diagnosis and monitoring. That matters because STIC lesions often arise in the fallopian tube and are too small for imaging to detect.
The key limit is stated by the authors themselves. Their results came from previously collected blood samples from women whose diagnoses were already known, and the test is not ready for clinical practice. They now plan long-term follow-up of further participants to assess how far in advance the method can identify changes that precede cancer.
That distinction is especially important for people with BRCA1 or BRCA2 mutations. Preventive removal of relevant organs can reduce risk but may involve loss of fertility and, before menopause, early menopause. A reliable test could eventually add information about whether pre-cancerous changes are present. The evidence reported so far does not support treating Tu-Stroma as routine screening or as a basis for preventive-surgery decisions; prospective studies must first show how it performs in real clinical settings.
Sources
- Nauka w Polsce · Fundacja PAP — Źródło: Nauka w Polsce (Fundacja PAP) (https://naukawpolsce.pl/) · Source date: 2026-11-16
Independent editorial content. WUA is not affiliated with any political party. 2026-11-16